Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase II Neoadjuvant Study of Temozolomide Alone or With Pegylated Interferon-alpha 2b in Patients With Resectable American Joint Committee on Cancer (AJCC) Stage IIIB/IIIC or Stage IV (M1a) Metastatic Melanoma
Brief Summary: The goal of this clinical research study is to learn if temozolomide alone or given with pegylated interferon alpha-2b can help to control metastatic melanoma. Researchers also want to study the safety of these 2 treatments.

Objectives:

1. To determine the anti-tumor activity (pathological response CR+PR) and toxicity of temozolomide (TMZ) alone or in combination with pegylated interferon alpha-2b (PGI) in patients with resectable stage IIIC or stage IV (M1a) metastatic melanoma prior to definitive surgical resection.
2. To determine the relapse-free survival, overall survival and the impact of tumor response to chemotherapy in these patients.
3. To differentiate the in vivo treatment effects of TMZ alone vs.TMZ plus PGI and correlate with clinical outcome by analysis the pre- and post-treatment tumors and peripheral blood mononuclear cells with respect to:

1) Known cellular and molecular markers of apoptosis and cell proliferation, 2) Promotor methylation status of the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT), 3) DNA sequence variability of tumor suppressor genes and DNA repair enzymes, 4) Tumor genomic expression profiles analysis by complementary DNA (cDNA) microarray and protein array


Options:
A: Arm Label: Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Placebo for Nivolumab, Biological: Placebo for Ipilimumab | Arm Label: Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Biological: Placebo for Nivolumab | Arm Label: Arm C: Ipilimumab+Placebo for Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab, Biological: Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab, Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab, Arm C: Ipilimumab+Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Placebo for Nivolumab; Assigned to Arm(s): Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab, Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab, Arm C: Ipilimumab+Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Placebo for Ipilimumab; Assigned to Arm(s): Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab
B: Arm Label: Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine
C: Arm Label: Temozolomide (TMZ); Type: EXPERIMENTAL; Interventions: Drug: Temozolomide (TMZ) | Arm Label: Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI); Type: EXPERIMENTAL; Interventions: Drug: Temozolomide (TMZ), Drug: Pegylated Interferon Alpha-2b (PGI) | Intervention Type: DRUG; Name: Temozolomide (TMZ); Assigned to Arm(s): Temozolomide (TMZ), Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI) | Intervention Type: DRUG; Name: Pegylated Interferon Alpha-2b (PGI); Assigned to Arm(s): Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI)
D: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Intervention Type: DRUG; Name: GSK2118436; Assigned to Arm(s): Single Arm

Answer: C